Company news

Vertex Pharmaceuticals Incorporated news in 2022

Vertex Pharmaceuticals Incorporated's news releases, calls and decks from 2022, newest first.

View company

Vertex Announces Investigational New Drug (IND) Application for VX-522, mRNA Therapy for People With Cystic Fibrosis, Cleared by FDA

December 11, 2022

Vertex and CRISPR Therapeutics to Present at the American Society of Hematology (ASH) Annual Meeting and Exposition

December 9, 2022

Vertex and Entrada Therapeutics Establish Collaboration to Discover and Develop Endosomal Escape Vehicle (EEV) Therapeutics for Myotonic Dystrophy Type 1 (DM1)

December 7, 2022

Vertex Announces Partnership with Basketball Hall-of-Famer Alonzo Mourning to Raise Awareness of APOL1-Mediated Kidney Disease (AMKD)

November 3, 2022

Vertex to Present New Data on its Portfolio of Cystic Fibrosis Medicines at the 2022 North American Cystic Fibrosis Conference

November 2, 2022

Vertex Reports Third Quarter 2022 Financial Results

October 26, 2022

Vertex to Announce Third Quarter 2022 Financial Results on October 27

October 12, 2022

Vertex Advances Program Targeting Alpha-1 Antitrypsin Deficiency

October 10, 2022

Vertex and CRISPR Therapeutics Announce Global exa-cel Regulatory Submissions for Sickle Cell Disease and Beta Thalassemia in 2022

September 26, 2022

Vertex Appoints Jonathan Biller as Chief Legal Officer

September 7, 2022

Vertex Announces U.S. FDA Approval for ORKAMBI® (lumacaftor/ivacaftor) in Children With Cystic Fibrosis Ages 12 to <24 months

September 1, 2022

Vertex to Participate in the Wells Fargo Healthcare Conference on Friday, September 9

August 30, 2022

Vertex Reports Second Quarter 2022 Financial Results

August 3, 2022

Vertex Advances VX-548 in Acute and Neuropathic Pain

July 21, 2022

Vertex and Verve Therapeutics Establish Collaboration to Discover and Develop an In Vivo Gene Editing Program for Liver Disease

July 19, 2022

Vertex to Announce Second Quarter 2022 Financial Results on August 4

July 17, 2022

Vertex to Acquire ViaCyte, With the Goal of Accelerating its Potentially Curative VX-880 Programs in Type 1 Diabetes

July 10, 2022

Vertex Announces Letter of Intent With the pan-Canadian Pharmaceutical Alliance for Public Reimbursement of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 and Older

July 7, 2022

Vertex Announces FDA Has Lifted the Clinical Hold on VX-880 Phase 1/2 Clinical Trial for the Treatment of Type 1 Diabetes

July 4, 2022

Vertex and CRISPR Therapeutics Present New Data on More Patients With Longer Follow-Up Treated With exagamglogene autotemcel (exa-cel) at the 2022 European Hematology Association (EHA) Congress

June 10, 2022

Vertex to Present Data Demonstrating Significant Benefits of Long-Term and Early Treatment With CFTR Modulators at the European Cystic Fibrosis Conference

June 9, 2022

Vertex to Participate in the Goldman Sachs 43rd Annual Healthcare Conference on June 15

June 7, 2022

Vertex Announces Inaxaplin (VX-147) Granted Breakthrough Therapy Designation by U.S. FDA and Priority Medicines (PRIME) Designation by the EMA

June 7, 2022

Vertex Presents New Data from VX-880 Phase 1/2 Clinical Trial at the American Diabetes Association 82nd Scientific Sessions

June 5, 2022

Vertex and CRISPR Therapeutics Announce Acceptance of Late-Breaking Abstract for CTX001™ at the 2022 Annual European Hematology Association (EHA) Congress

June 1, 2022

Vertex to Present New Data on VX-880 Clinical Trial at 82nd American Diabetes Association Annual Conference

May 30, 2022

Suketu Upadhyay Elected to Vertex Board of Directors

May 17, 2022

Vertex Announces Further Expansion in the Boston Seaport at Dedication of the Jeffrey Leiden Center for Cell and Genetic Therapies

May 16, 2022

Vertex Announces $50 Million Commitment to Health Equity With Three Initial Grants

May 16, 2022

Vertex Reports First Quarter 2022 Financial Results

May 4, 2022

Vertex to Announce First Quarter 2022 Financial Results on May 5

April 20, 2022

Health Canada Grants Marketing Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 Through 11 years With At Least One F508del Mutation

April 20, 2022

Health Canada Grants Marketing Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 Through 11 years With At Least One F508del Mutation

April 19, 2022

Vertex Announces Statistically Significant and Clinically Meaningful Results From Two Phase 2 Proof-of-Concept Studies of VX-548 for the Treatment of Acute Pain

March 30, 2022

Vertex Announces Reimbursement Agreement in Australia for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for Patients With Cystic Fibrosis Ages 12 Years and Older With at Least One F508del Mutation in the CFTR Gene

March 25, 2022

Health Canada Grants Marketing Authorization for KALYDECO® (ivacaftor) for Patients With Cystic Fibrosis Between the Ages of 4 Months and 18 Years With the R117H Mutation in the CFTR Gene

March 25, 2022

Vertex Advances VX-147 Into Pivotal Clinical Development for People With APOL1-Mediated Kidney Disease

March 21, 2022

Vertex to Present at Cowen’s 42nd Annual Health Care Conference on March 8

February 28, 2022

Vertex Reports Fourth Quarter 2021 and Full Year Financial Results

January 25, 2022

Vertex to Announce Fourth Quarter 2021 Financial Results on January 26

January 17, 2022

European Commission Approves KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat Children With Cystic Fibrosis Ages 6 to 11 Years

January 10, 2022

Vertex to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 10

January 3, 2022

Calls in 2022

Decks in 2022